Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 15/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13853082 | 1.00 | CHRM1 (0.51) | CHRM1ALDH1A1GAAENPP2CHRM4 | |
| SCHEMBL13686569 | 1.00 | CHRM1 (0.51) | CHRM1ALDH1A1GAAENPP2CHRM4 | |
| SCHEMBL2226038 | 0.82 | CHRM1 (0.62) | CHRM1ALDH1A1GAACHRM4CHRM5 | |
| SCHEMBL13686549 | 0.81 | CHRM1 (0.55) | CHRM1ALDH1A1GAACHRM4CHRM5 | |
| SCHEMBL3870222 | 0.81 | CHRM1 (0.50) | CHRM1ALDH1A1GAACHRM4CHRM5 | |
| SCHEMBL13686551 | 0.81 | CHRM1 (0.50) | CHRM1ALDH1A1GAACHRM4CHRM5 | |
| SCHEMBL13853080 | 0.81 | CHRM1 (0.50) | CHRM1ALDH1A1GAACHRM4CHRM5 | |
| SCHEMBL13853380 | 0.79 | ALDH1A1 (0.34) | CHRM1ALDH1A1GAA | |
| SCHEMBL13686552 | 0.79 | CHRM1 (0.49) | CHRM1ALDH1A1GAACHRM4CHRM5 | |
| SCHEMBL13686550 | 0.79 | CHRM1 (0.49) | CHRM1ALDH1A1GAACHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | CCR1, CCR3, CCR8 | CHRM1 394/4885ALDH1A1 628/4885GAA 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.